Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment manufactured by Beacon Pharmaceuticals Limited. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).
Like What You See?
Years in Business